Last reviewed · How we verify
Alternative medications: carboplatin
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells. Used for Ovarian cancer, Non-small cell lung cancer, Small cell lung cancer.
At a glance
| Generic name | Alternative medications: carboplatin |
|---|---|
| Sponsor | Universität des Saarlandes |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. This leads to apoptosis in cancer cells. It is a second-generation platinum compound designed to have a more favorable toxicity profile than cisplatin while maintaining anti-tumor efficacy.
Approved indications
- Ovarian cancer
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck cancer
- Breast cancer
- Testicular cancer
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (PHASE3)
- Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (PHASE3)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy
- Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alternative medications: carboplatin CI brief — competitive landscape report
- Alternative medications: carboplatin updates RSS · CI watch RSS
- Universität des Saarlandes portfolio CI